Loss of B1 and marginal zone B cells during ovarian cancer

Jeffrey Maslanka & James E. Riggs et al. · 2023-11-22

1Citations
Recent advances in immunotherapy have not addressed the challenge presented by ovarian cancer. Although the peritoneum is an "accessible" locus for this disease there has been limited characterization of the immunobiology therein. We investigated the ID8-C57BL/6J ovarian cancer model and found marked depletion of B1 cells from the ascites of the peritoneal cavity. There was also selective loss of the B1 and marginal zone B cell subsets from the spleen. Immunity to antigens that activate these subsets validated their loss rather than relocation. A marked influx of myeloid-derived suppressor cells correlated with B cell subset depletion. These observations are discussed in the context of the housekeeping burden placed on innate B cells during ovarian cancer and to foster consideration of B cell biology in therapeutic strategies to address this challenge.
TL;DR

This work investigated the ID8-C57BL/6J ovarian cancer model and found marked depletion of B1 cells from the ascites of the peritoneal cavity and a marked influx of myeloid-derived suppressor cells correlated with B cell subset depletion.

AI-generated by Semantic Scholar

Authors
Jeffrey Maslanka, Gretel Torres, Jennifer Londregan, Naomi Goldman, Daniel Silberman, John Somerville, James E. Riggs
Funding
Immunoregulation in the Peritoneal CavityMacrophage Density Regulates T CellsImmunoregulation in the Peritoneal CavityMacrophage Density Regulates T Cells

NIAID NIH HHS

R15 AI060356

NCI NIH HHS

R15 CA136901

National Institutes of Health

R15 AI 060356-01

National Institutes of Health

R15 CA 136901